Humanwell's subsidiary gains approval for progesterone soft capsules

Humanwell Healthcare Group (SSE:600079) announced that its subsidiary, Wuhan Jiulong Renfu Pharmaceutical, has been granted drug registration certificates from the National Medical Products Administration for its Progesterone Soft Capsules. The capsules, available in 0.2g and 0.1g dosages, are classified as Category 4 chemical drugs and are indicated for treating disorders caused by progesterone deficiency, aiding in pregnancy. Manufacturing will be handled by Humanwell Puke Pharmaceutical (Wuhan) Co., Ltd, a wholly-owned subsidiary of Humanwell.